Preferred Label : Daratumumab and Recombinant Human Hyaluronidase;
NCIt synonyms : DARA/rHuPH20; Daratumumab rHuPH20; Daratumumab/rHuPH20 Co-formulation; DARA Co-formulated with rHuPH20; Daratumumab with rHuPH20; HuMax-CD38-rHuPH20; Darzalex/rHuPH20; Recombinant Human Hyaluronidase Mixed with Daratumumab; Daratumumab/Hyaluronidase-fihj; Daratumumab and Hyaluronidase-fihj; Daratumumab and Vorhyaluronidase Alfa;
NCIt related terms : Daratumumab and hyaluronidase; Daratumumab and vorhyaluronidase;
NCIt definition : A co-formulation composed of daratumumab, a human immunoglobulin (Ig) G1 kappa monoclonal
antibody directed against the cell surface glycoprotein cluster of differentiation
38 (CD-38; CD38), and a recombinant form of human hyaluronidase (rHuPH20), with potential
antineoplastic activity. Upon subcutaneous administration of daratumumab and hyaluronidase-fihj,
daratumumab targets and binds to CD38 on certain CD38-expressing tumors, such as multiple
myeloma (MM) and plasma cell leukemia. This binding induces direct apoptosis through
Fc-mediated cross-linking and triggers immune-mediated tumor cell lysis through antibody-dependent
cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent
cellular phagocytosis (ADCP) immune responses. CD38, a transmembrane glycoprotein,
is expressed in both hematopoietic and non-hematopoietic lineage cells. Hyaluronidase-fihj
hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing
interstitial viscosity and enhancing penetration of daratumumab through the interstitial
space. This facilitates the delivery of daratumumab to CD38-expressing tumor cells.;
Drug name : Darzalex Faspro; Darzquro;
Molecule name : Daratumumab-rHuPH20;
NCI Metathesaurus CUI : CL563089;
Codes from synonyms : 4940; 120089;
Origin ID : C156401;
UMLS CUI : C5400124;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
